Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma for COVID-19
NCT04554992Phase 1Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- Mar 2020
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19), sponsored by Houston Methodist Research Institute. Primary endpoints: Cumulative incidence of serious adverse events at 60 days and Mortality at Day 28. Started Mar 2020; status: completed.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04554992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04554992.